Patents by Inventor Eric Pierre Alexandre Arnoult

Eric Pierre Alexandre Arnoult has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS
    Publication number: 20150299221
    Abstract: This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 22, 2015
    Inventors: Jean-Francois Bonfanti, Jerome Michel Claude Fortin, Philippe Muller, Frederic Marc Maurice Doublet, Pierre Jean-Marie Bernard Raboisson, Eric Pierre Alexandre Arnoult
  • Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Publication number: 20150080413
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Jerome Emile Georges Guillemont, David Francis Alain Lancois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 8906923
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: December 9, 2014
    Assignee: Janssen R&D Ireland
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • Methods for identifying inhibitors against viruses that use a class I fusion protein
    Patent number: 8898047
    Abstract: The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I fusion protein may be effective for treating, for example, respiratory infections by Respiratory Syncytial Virus (RSV).
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: November 25, 2014
    Assignee: Janssen Pharmaceuticals NV
    Inventors: Dirk André Emmy Roymans, Hendrik Leon Augusta Jozef De Bondt, Eric Pierre Alexandre Arnoult, Herman Van Vlijmen, Jean-François Bonfanti
  • Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Publication number: 20140171451
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Application
    Filed: August 10, 2012
    Publication date: June 19, 2014
    Applicant: Janssen R&D Ireland
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans, Eric Pierre Alexandre Arnoult
  • METHODS FOR IDENTIFIYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN
    Publication number: 20110009408
    Abstract: The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I fusion protein may be effective for treating, for example, respiratory infections by Respiratory Syncytial Virus (RSV).
    Type: Application
    Filed: February 26, 2009
    Publication date: January 13, 2011
    Inventors: Dirk André Emmy Roymans, Hendrik Leon Augusta Jozef De Bondt, Eric Pierre Alexandre Arnoult, Herman Van Vlijmen, Jean-François Bonfanti